An observational study in Ondine Syndrome (Congenital Central Hypoventilation Syndrome), sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 7 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Sleep Apnea, Central with a site in France — 3 open to participants now, 3 under way, none of them phase 3. Sleep Apnea, Central · France.
Among the 14 studies in Sleep Apnea, Central with a site in France, this one is the only one that started in 2025, is one of 8 observational ones, and was the 14th registered.
96 studies on the registry are indexed under Sleep Apnea, Central; 18 are open to participants now.
Browse Sleep Apnea, Central studies →3 of the 14 studies in Sleep Apnea, Central with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 6–16
University Hospital, Grenoble · Sites in France
Ages 18–85
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 13 Sleep Apnea, Central studies recruiting now, 8 (62%) set no upper age limit and 3 (23%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 7 Years to 20 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 148 across 36 observational studies indexed under Sleep Apnea, Central.
Median enrollment 104 across the 6 interventional studies, 287 across the 8 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 14 have an industry lead sponsor. The 8 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 4 studies filed under Sleep Apnea, Central — fewer than ten, so there is no comparison to draw.
1 of the studies in Sleep Apnea, Central with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07081464Assistance Publique - Hôpitaux de ParisLocus Coeruleus and CCHS (Congenital Central Hypoventilation Syndrome) | 2027-11-15 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Sleep Apnea, Central with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates whether cognitive dysfunction in young patients with congenital central hypoventilation syndrome (Ondine Syndrome) is related to the severity of the disease and dysfunction of the locus coeruleus (a brainstem structure involved in autonomic control and cognition). The investigators will assess cognitive evoked potentials (P300 wave) using high-resolution EEG during attention tasks, pupillometry, brain MRI, neuropsychological tests, and heart rate variability. Patients with different severities of PHOX2B gene mutation (alanine expansions \<27 vs. ≥27) will be compared.
Ondine Syndrome (congenital central hypoventilation syndrome) is a rare autosomal dominant genetic disorder caused by mutations in PHOX2B. Patients require lifelong nocturnal ventilation and often have cognitive impairments. The cause of cognitive deficits is uncertain: possible hypoxic brain injury or direct effects of PHOX2B mutations on brain regions like the locus coeruleus.
This cross-sectional study includes 21 patients aged 7-20 years with Ondine Syndrome and PARM-type (polyalanine repeat mutation) PHOX2B mutations, divided into moderate (\<27 alanine expansions) and severe (≥27 expansions) groups. During routine hospitalization, participants undergo:
High-resolution EEG with evoked potentials during auditory and visual attention tasks to measure P300 wave amplitude.
Pupillometry during the same tasks to assess locus coeruleus function.
3T (3 Tesla magnetic resonance imaging) MRI (anatomical and diffusion imaging) without sedation.
Neuropsychological assessment with the Vineland test.
Holter ECG to analyze heart rate variability.
The goal is to link locus coeruleus dysfunction to disease severity and explore its impact on cognition, autonomic balance, and sleep."
Minors and young adults aged 7 to 20 years diagnosed neonatally with Ondine Syndrome, carrying a PARM-type PHOX2B mutation and requiring nocturnal ventilation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: MRI, EEG, Pupillometry
Other: MRI, EEG, Pupillometry
Comparison of P300 wave amplitude, pupillometric responses, functional and structural brain connectivity, socio-adaptive function, cardiac autonomic balance between two phenotypic severity groups of young patients with Ondine Syndrome.
Amplitude of the P300 wave (peak-to-baseline) recorded by high-resolution EEG during visual and auditory attention tasks.
Measurement of cognitive evoked potential P300 amplitude using a 64-electrode EEG system during Flanker and oddball paradigms to assess locus coeruleus function.
Time frame: 24 hours
Ratio of maximal pupil diameter during attention tasks to resting pupil diameter measured by pupillometry.
Time frame: 24 hours
Functional connectivity parameters of the locus coeruleus measured by high-resolution EEG and 3T brain MRI diffusion imaging.
Time frame: 24 hours
Scores of socio-adaptive behavior from the Vineland neuropsychological test (Vineland Adaptative Behavior Scales II, with scores ranging from 20 to 160; higher scores indicating better functioning).
Vineland Adaptative Behavior Scales II, with scores ranging from 20 to 160; higher scores indicating better functioning.
Time frame: 24 hours
Heart rate variability parameters from Holter ECG monitoring.
Time frame: 24 hours
Structural connectivity parameters of the locus coeruleus measured by high-resolution EEG and 3T brain MRI diffusion imaging.
Time frame: 24 hours
Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Oct 2025 → Nov 2025, primary completion Oct 2027 → Nov 2027 and completion Oct 2027 → Nov 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →